HFpEF による Cpc-PH の治療のためのソタテルセプトの研究 (MK-7962-007/A011-16) (CADENCE)
駆出率が保存された心不全による後毛細血管および前毛細血管肺高血圧症(Cpc-PH)の治療に対するソタテルセプトとプラセボの効果を評価する第2相、二重盲検、無作為化、プラセボ対照試験
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
調査の概要
状態
条件
詳細な説明
Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.
As of protocol amendment 6, the 18-month Extension Period is being removed. Participants who have completed at least the 24-week placebo controlled treatment period and the end of study visit, and who have not discontinued study treatment early, may be eligible to participate in an extension study.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85032
- PULMONARY ASSOCIATES, P.A. ( Site 1008)
-
Tucson、Arizona、アメリカ、85724-0001
- University of Arizona ( Site 1006)
-
-
California
-
La Jolla、California、アメリカ、92037-1205
- Scripps Clinic ( Site 4001)
-
Los Angeles、California、アメリカ、90048
- Cedars Sinai Medical Center ( Site 1082)
-
Orange、California、アメリカ、92868
- University of California Irvine ( Site 1086)
-
Santa Barbara、California、アメリカ、93105-5311
- Jeffrey S.Sager MD Medical Corporation ( Site 1060)
-
Stanford、California、アメリカ、94305
- Stanford University ( Site 1024)
-
Torrance、California、アメリカ、90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University Of Colorado ( Site 1013)
-
Littleton、Colorado、アメリカ、80120
- South Denver Cardiology Associates ( Site 1091)
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06519-1304
- Winchester Chest Clinic ( Site 1093)
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20037-3201
- The George Washington University Medical Faculty Associates ( Site 1025)
-
-
Florida
-
Brandon、Florida、アメリカ、33511
- Bay Area Cardiology ( Site 1071)
-
Jacksonville、Florida、アメリカ、32224
- Mayo Clinic Jacksonville - PPDS ( Site 1045)
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando ( Site 1058)
-
Tampa、Florida、アメリカ、33606
- Tampa General Hospital ( Site 1043)
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30309-1281
- Piedmont Atlanta Hospital ( Site 1085)
-
Atlanta、Georgia、アメリカ、30322-1013
- Emory University ( Site 1030)
-
-
Idaho
-
Boise、Idaho、アメリカ、83704-8880
- Saint Alphonsus Regional Medical Center ( Site 1097)
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- University of Illinois Hospital ( Site 1095)
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202-1218
- IU Health Advanced Heart and Lung Care ( Site 1092)
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Medical Group St. Vincent ( Site 1076)
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Hospital and Clinics ( Site 1050)
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Medical Center ( Site 1020)
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- Norton Pulmonary Specialists ( Site 1066)
-
Louisville、Kentucky、アメリカ、40202
- University of Louisville ( Site 1099)
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- University Medical Center New Orleans ( Site 1057)
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center - PPDS ( Site 1012)
-
Boston、Massachusetts、アメリカ、02115
- Brigham and Women's Hospital [Boston, MA] ( Site 1014)
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan ( Site 1011)
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota Hospitals ( Site 1062)
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine [Saint Louis, MO] ( Site 1022)
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center ( Site 1053)
-
-
New York
-
Liverpool、New York、アメリカ、13088
- Pulmonary Health Physicians ( Site 1080)
-
New York、New York、アメリカ、10021-9800
- Weill Cornell Medical College ( Site 1046)
-
Rochester、New York、アメリカ、14642
- University of Rochester Medical Center - PPDS ( Site 1039)
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710-4000
- Duke University Medical Center ( Site 1026)
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Cleveland Medical Center ( Site 1005)
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation ( Site 1065)
-
Columbus、Ohio、アメリカ、43210
- The Ohio State University Wexner Medical Center ( Site 1032)
-
Toledo、Ohio、アメリカ、43614
- University of Toledo Medical Center ( Site 1070)
-
-
Oregon
-
Portland、Oregon、アメリカ、97126
- Oregon Health Science University ( Site 1054)
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15212-4737
- Allegheny General Hospital ( Site 1088)
-
Wynnewood、Pennsylvania、アメリカ、19096
- Lankenau Institute for Medical Research ( Site 1089)
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital ( Site 1033)
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425-0001
- Medical University of South Carolina - PPDS ( Site 1003)
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37919
- Statcare Pulmonary Consultants - Knoxville ( Site 1031)
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Baylor University Medical Center ( Site 1096)
-
Dallas、Texas、アメリカ、75390
- University of Texas Southwestern Medical Center ( Site 4002)
-
-
Utah
-
Murray、Utah、アメリカ、84107
- Intermountain Medical Center ( Site 1079)
-
-
Virginia
-
Falls Church、Virginia、アメリカ、22042
- Inova Heart and Vascular Institute ( Site 1078)
-
Richmond、Virginia、アメリカ、23226
- Bon Secours St. Mary's Hospital ( Site 1069)
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University ( Site 1081)
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora St Luke's Medical Center ( Site 1083)
-
Milwaukee、Wisconsin、アメリカ、53226
- Froedtert Hospital & the Medical College of Wisconsin ( Site 1051)
-
-
-
-
London, City of
-
London、London, City of、イギリス、W12 0HS
- Imperial College Healthcare NHS Trust ( Site 1203)
-
-
-
-
-
Ashdod、イスラエル、7747629
- Assuta Ashdod Medical Center ( Site 1710)
-
Be’er Ya‘aqov、イスラエル、70300
- Shamir Medical Center Assaf Harofeh ( Site 1713)
-
Haifa、イスラエル、3436212
- Lady Davis Carmel Medical Center ( Site 1705)
-
Haifa、イスラエル、3109601
- Rambam Health Corp. ( Site 1716)
-
Holon、イスラエル、5810001
- Edith Wolfson Medical Center ( Site 1717)
-
Jerusalem、イスラエル、91031
- Shaare Zedek Medical Center ( Site 1715)
-
Jerusalem、イスラエル、91120
- Hadassah Ein Kerem Medical Center ( Site 1711)
-
Kfar Saba、イスラエル、4428164
- Meir Medical Center. ( Site 1707)
-
Petah Tikva、イスラエル、4941492
- Rabin Medical Center ( Site 1703)
-
Rehovot、イスラエル、7610001
- Kaplan Medical Center ( Site 1712)
-
Safed、イスラエル、13100
- ZIV Medical Center ( Site 1704)
-
Tel Aviv、イスラエル、64239
- Tel Aviv Sourasky Medical Center ( Site 1714)
-
-
-
-
-
Bergamo、イタリア、24127
- ASST Papa Giovanni XXIII ( Site 2410)
-
Roma、イタリア、00161
- Azienda Policlinico Umberto I ( Site 2402)
-
-
Emilia-Romagna
-
Bologna、Emilia-Romagna、イタリア、40138
- AOU di Bologna Policlinico S Orsola Malpighi ( Site 2409)
-
-
Friuli Venezia Giulia
-
Trieste、Friuli Venezia Giulia、イタリア、34149
- Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) ( Site 2405)
-
-
Lombardy
-
Monza、Lombardy、イタリア、20900
- Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza - A. O. San Gerardo ( Site 2406)
-
Pavia、Lombardy、イタリア、27100
- Fondazione IRCCS-Policlinico San Matteo ( Site 2401)
-
-
Sardinia
-
Sassari、Sardinia、イタリア、07100
- Ospedale SS Annunziata ( Site 2408)
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 2B7
- University Of Alberta ( Site 2101)
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8L 2X2
- Hamilton General Hospital-Special Immunology Services Clinic ( Site 2110)
-
Toronto、Ontario、カナダ、M5G 2N2
- University Health Network ( Site 2109)
-
-
Quebec
-
Sainte-Foy、Quebec、カナダ、G1V 4G5
- Institut Universitaire de Cardiologie et de Pneumologie ( Site 2107)
-
-
-
-
Västra Götaland County
-
Gothenburg、Västra Götaland County、スウェーデン、413 45
- Sahlgrenska Universitetssjukhuset ( Site 3201)
-
-
-
-
-
Barcelona、スペイン、08036
- Hospital Clinic de Barcelona ( Site 1602)
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre ( Site 1603)
-
Seville、スペイン、41009
- Hospital Universitario Virgen Macarena ( Site 1612)
-
Toledo、スペイン、41007
- Hospital Universitario de Toledo ( Site 1607)
-
-
Madrid
-
Majadahonda、Madrid、スペイン、28222
- Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1604)
-
-
Malaga
-
Marbella、Malaga、スペイン、29603
- Hospital Costa del Sol ( Site 1613)
-
-
-
-
-
Berlin、ドイツ、14050
- DRK Kliniken Berlin Westend ( Site 1507)
-
-
Baden-Wurttemberg
-
Heidelberg、Baden-Wurttemberg、ドイツ、69126
- Thoraxklinik-Heidelberg gGmbH ( Site 1509)
-
-
Bavaria
-
München、Bavaria、ドイツ、80639
- Krankenhaus Neuwittelsbach ( Site 1510)
-
Regensburg、Bavaria、ドイツ、93053
- University Hospital Regensburg ( Site 1503)
-
-
Hesse
-
Bad Nauheim、Hesse、ドイツ、61231
- Kerckhoff-Klinik-Forschungs-GmbH ( Site 1514)
-
Giessen、Hesse、ドイツ、35392
- Universitätsklinikum Gießen und Marburg GmbH ( Site 1512)
-
-
Lower Saxony
-
Hanover、Lower Saxony、ドイツ、30625
- Medizinische Hochschule Hannover ( Site 1505)
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、50931
- Uniklinik Köln ( Site 1511)
-
-
Rhineland-Palatinate
-
Mainz、Rhineland-Palatinate、ドイツ、55131
- Universitaetsmedizin Johannes Gutenberg Universitaet Mainz ( Site 1515)
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- Universitätsklinikum Carl Gustav Carus an der TU Dresden. ( Site 1501)
-
-
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06000
- Hôpital Pasteur - CHU Nice ( Site 1311)
-
-
Doubs
-
Besançon、Doubs、フランス、25000
- Centre Hospitalier Universitaire du Besancon ( Site 1324)
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、フランス、31400
- Hopital de Rangueil du Toulouse ( Site 1322)
-
-
Herault
-
Montpellier、Herault、フランス、34090
- CHU Montpellier Hôpital Arnaud de VIlleneuve ( Site 1301)
-
-
Ille-et-Vilaine
-
Rennes、Ille-et-Vilaine、フランス、35033
- Hôpital Pontchaillou ( Site 1319)
-
-
Isere
-
Grenoble、Isere、フランス、38043
- Centre Hospitalier Universitaire de Grenoble ( Site 1303)
-
-
Loire-Atlantique
-
Nantes、Loire-Atlantique、フランス、44000
- CHU de Nantes - Hoptal Nord Laennec ( Site 1309)
-
-
Maine-et-Loire
-
Angers、Maine-et-Loire、フランス、49933
- CHU Angers ( Site 1313)
-
-
Meurthe-et-Moselle
-
Vandœuvre-lès-Nancy、Meurthe-et-Moselle、フランス、54500
- CHRU de Nancy Hopitaux de Brabois ( Site 1308)
-
-
Nord
-
Lille、Nord、フランス、59037
- CHRU Lille ( Site 1306)
-
-
Seine-Maritime
-
Rouen、Seine-Maritime、フランス、76000
- CHU de Rouen ( Site 1323)
-
-
Val-de-Marne
-
Le Kremlin-Bicêtre、Val-de-Marne、フランス、94270
- Centre Hospitalier Universitaire de Bicetre ( Site 1304)
-
-
-
-
Bruxelles-Capitale, Region de
-
Anderlecht、Bruxelles-Capitale, Region de、ベルギー、1070
- Hôpital Erasme ( Site 1402)
-
-
Vlaams-Brabant
-
Leuven、Vlaams-Brabant、ベルギー、3000
- UZ Leuven - Campus Gasthuisberg ( Site 1401)
-
-
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-202
- Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2801)
-
-
Lublin Voivodeship
-
Lubin、Lublin Voivodeship、ポーランド、20-718
- Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego ( Site 2806)
-
-
Masovian Voivodeship
-
Otwock、Masovian Voivodeship、ポーランド、05-400
- Europejskie Centrum Zdrowia Otwock Szpital im Fryderyka Chopina ( Site 2802)
-
Warsaw、Masovian Voivodeship、ポーランド、02-507
- Państwowy Instytut Medyczny MSWiA ( Site 2805)
-
-
Podlaskie Voivodeship
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-276
- Uniwersytecki Szpital Kliniczny w Bialymstoku - Marii Sklodowskiej-Curie 24A ( Site 2803)
-
-
West Pomeranian Voivodeship
-
Szczecin、West Pomeranian Voivodeship、ポーランド、70-111
- Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie ( Site 2804)
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、ポーランド、91-347
- Wojewodzki Specjalistyczny Szpital im dr WI Bieganskiego w Lodzi ( Site 2807)
-
-
-
-
Nuevo León
-
Monterrey、Nuevo León、メキシコ、64710
- Unidad de Investigacion Clinica En Medicina SC ( Site 2505)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Participants must meet the following criteria to be enrolled in this proof-of-concept study:
-
Age 18 to 85 years
-
Clinical diagnosis of HFpEF:
• Left ventricular ejection fraction ≥50%, with no history of LVEF below 45% in more than two consecutive measurements under stable conditions
-
Demonstrated Cpc-PH by all of the following:
- Baseline RHC performed within 28 days of randomization documenting a minimum PVR of ≥320 dyn•sec/cm5 (4 wood units)
- Mean pulmonary arterial pressure (mPAP) of >20 mmHg
- Pulmonary capillary wedge pressure (PCWP) >15 mmHg but < 30 mmHg
-
New York Heart Association FC of II or III
-
Six-minute Walk Distance ≥100 m repeated twice during Screening and both values within 15% of each other, calculated from the highest value
-
Chronic medication for HF or for any underlying condition, administered at a stable (per investigator) dose for ≥30 days prior to Visit 1. Diuretics and/or anticoagulants are excepted from this rule but should not be newly started or stopped within 30 days of Visit 1, and a prescribed dose change should not occur within 7 days of Visit 1. Anticoagulation may be suspended for RHC if necessary
-
Women of childbearing potential must:
- Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
- If sexually active with a male partner: use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
- Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug
-
Male participants must:
- Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
- Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug
-
Ability to adhere to the study visit schedule and understand and comply with all protocol requirements
-
Agreement to not participate in any other trials of investigational drugs/devices while enrolled in the A011-16 study
-
Ability to understand and provide documented consent for participation
Exclusion Criteria:
Participants will be excluded from the study if any of the following criteria are met:
-
A diagnosis of PH in WHO Group 1, WHO Group 3, WHO Group 4, or WHO Group 5
-
Clinically significant and active lung disease:
- Chronic obstructive pulmonary disease with post-bronchodilator forced expiratory volume in the first second (FEV1) <60% predicted
- Restrictive lung disease with total lung capacity <70% predicted
- More than mild interstitial lung disease (ILD), with FVC<70% or FEV1<60% predicted (still appropriate if absence of more than mild ILD, fibrosis, or COPD on computed tomography [CT] imaging)
-
Cardiovascular co-morbidities, which include any of the following:
- History of more than mild mitral or aortic stenosis
- Ongoing more than mild mitral or aortic regurgitation
- More than one valve replacement or repair (mechanical or biomechanical) or anticipation of any valve replacement or repair
- Severe tricuspid regurgitation due to primary valvular disease
- Occurrence of myocardial infarction, acute coronary syndrome, coronary artery bypass graft or percutaneous coronary intervention within 180 days of Visit 1
- History of serious life-threatening or hemodynamically significant arrhythmia
- History of or anticipated heart transplant or ventricular assist device implantation
- History of implantable cardioverter defibrillator placement or anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening
- Anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening or history of implantable cardioverter defibrillator placement
- Occurrence of myocardial infarction within 180 days of Visit 1
- History of known pericardial constriction, hypertrophic cardiomyopathy, sarcoidosis, or amyloid cardiomyopathy
- Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mmHg or sitting diastolic blood pressure >110 mmHg during Screening after a period of rest
- Systemic hypotension as evidenced by sitting systolic blood pressure <90 mmHg or sitting diastolic blood pressure <50 mmHg during Screening
- Resting heart rate of <45 bpm or >115 bpm
- Stroke within 90 days of Visit 1
- Acutely decompensated HF that required hospitalization within 30 days of Visit 1
- Electrocardiogram during Screening Period with Fridericia's corrected QT interval (QTcF) >470 msec for males or >480 msec for females, or >500 msec if a ventricular conduction defect (right bundle branch block; left bundle branch block; or interventricular conduction delay) is present
- Personal or family history of Brugada syndrome, sudden cardiac arrest or unexplained sudden cardiac death or arrest
- Personal or family history of long QT syndrome unless the participant's ECG shows a normal QTc
- Arrhythmogenic right ventricular dysplasia (ARVD) unless the participant has a recent cardiac MRI that shows no evidence of this diagnosis
-
Hospitalization for any worsening of medical conditions or any significant surgery per investigator within 30 days of Visit 1
-
Received any approved PAH-specific therapies (i.e., endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators) within 30 days of Visit 1.The use of an oral phosphodiesterase type 5 inhibitor, if only indicated for erectile dysfunction, is permitted, if not administered within 48 hours of a study visit or procedure
-
Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin, or levosimendan) within 30 days of Visit 1
-
Received erythropoietin within 6 months of Visit 1
-
Known history of chronic liver disease, including untreated hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), with severe hepatic impairment and/or cirrhosis (e.g., hepatic encephalopathy)
-
Prior exposure to sotatercept or luspatercept
-
Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented consent
-
Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days of Visit 1 or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
-
Any of the following clinical laboratory values prior to Visit 1 as specified:
- Hemoglobin (Hgb) above the gender-specific upper limit of normal (ULN) per local laboratory test within 28 days of Visit 1or <10 g/dL per local laboratory within 28 days of Visit 1
- Serum alanine aminotransferase or aspartate aminotransferase levels >3× ULN or total bilirubin >3× ULN within 28 days of Visit 1
- Estimated glomerular filtration rate <30 ml/min/1.73 m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of Visit 1 or required renal replacement therapy within 90 days of Visit 1
- Glycated hemoglobin (HbA1c) >10% within 28 days of Visit 1
- Platelet count < 75,000/mm3 within 28 days of Visit 1
-
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in the investigational product
-
Major surgery within 60 days of Visit 1. Participants must have completely recovered from any previous surgery prior to Visit 1
-
Prior organ transplantation (e.g., heart, lung, liver, kidney), bone marrow transplantation, or life expectancy of < 12 months
-
Pregnancy or breastfeeding in females
-
Active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤ 2 squamous cell carcinomas of the skin
-
History of clinically significant (as determined by the investigator) endocrine, hematologic, hepatic, (auto)immune, infectious (requiring chronic antibiotics), metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or another disease that may limit participation in the study
-
Body mass index ≥50 kg/m2
-
More than mild obstructive sleep apnea (treated or untreated)
-
Any non-cardiopulmonary condition or acute/chronic impairment(s) (other than dyspnea) that limits the ability to perform 6-minute walk test (6MWT)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period. |
Administered by subcutaneous injection |
|
実験的:Sotatercept 0.3 mg/kg
Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period. |
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
他の名前:
|
|
実験的:Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg
Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period. |
Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
時間枠:Baseline and Week 24
|
PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24
時間枠:Baseline and Week 24
|
The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24
時間枠:24 Weeks
|
Clinical Worsening events were defined as the number of weeks from first dose date to any of the following:
|
24 Weeks
|
|
Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24
時間枠:Baseline and Week 24
|
mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24
時間枠:Baseline and Week 24
|
PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24
時間枠:Baseline and Week 24
|
TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24
時間枠:Baseline and Week 24
|
RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24
時間枠:Baseline and Week 24
|
LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24
時間枠:Baseline and Week 24
|
IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24
時間枠:Baseline and Week 24
|
E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24
時間枠:Baseline and Week 24
|
E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24
時間枠:Baseline and Week 24
|
NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24
時間枠:Baseline and Week 24
|
NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea [shortness of breath]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea [shortness of breath]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC. |
Baseline and Week 24
|
|
Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24
時間枠:Baseline and Week 24
|
MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets. |
Baseline and Week 24
|
|
Base Study: Number of Participants With One or More Adverse Events (AEs)
時間枠:Up to approximately 6 months
|
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported. |
Up to approximately 6 months
|
|
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
時間枠:Up to approximately 6 months
|
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported. |
Up to approximately 6 months
|
協力者と研究者
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 7962-007
- A011-16 (その他の識別子:Acceleronpharma)
- MK-7962-007 (その他の識別子:MSD)
- 2021-003020-32 (EudraCT番号)
- U1111-1309-6433 (レジストリ識別子:UTN)
- 2023-509141-12-00 (レジストリ識別子:EU CT)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。